Session 2 Posters (Sorted by Poster Number)
Link to Poster Session 1 – Tuesday 16:00–18:00
| Submission Id | Poster number | Primary Topic | Presenting | Title |
|---|---|---|---|---|
| 8 | P-070 | Complement therapeutics | Paulina Dabrowska-Schlepp | Moss-produced complement factor H (CPV-104) as a therapeutic regulator in complement-mediated diseases. |
| 19 | P-073 | Complement therapeutics | Matthew Hardy | Pre-clinical characterization of CSL040, a soluble complement receptor 1 (CR1) fragment |
| 30 | P-077 | Complement therapeutics | Kevin Budding | Characterization and efficacy of a C2-blocking antibody in a rat kidney transplant model |
| 34 | P-078 | Complement therapeutics | Cedric Cui | Exploring the Role of the Terminal Complement Pathway in the DSS-Induced Colitis Model of Inflammatory Bowel Disease |
| 37 | P-079 | Complement therapeutics | Ruben Pio | Targeting C5a/C5aR1-mediated NETosis restores immunotherapy response in STK11-mutant lung cancer |
| 54 | P-082 | Complement therapeutics | Richard Clark | Development of novel peptide ligands with improved selectivity and pharmacological properties for complement system receptors. |
| 57 | P-083 | Complement therapeutics | Kevin Marchbank | AAV-mHDM-FH: Safety and expression profile in two murine models of hyper-complement activation |
| 71 | P-084 | Complement therapeutics | Jenny Fung | Targeting C5a Inflammation in ALS: Ex Vivo Findings from PMX205 Phase Ib Trial |
| 92 | P-087 | Complement therapeutics | William MacIntosh-Smith | Mapping inhibitory epitopes on C7 with monoclonal antibodies |
| 99 | P-088 | Complement therapeutics | Inez Trambas | The enigmatic role of C5aR2 in diabetic kidney disease |
| 102 | P-089 | Complement therapeutics | Yuzhihan Cao | Motor neuron disease C9orf72 dipeptides mediate neurotoxicity in human brain organoids through activation of C5aR1 |
| 103 | P-090 | Complement therapeutics | Vitalijs Ovcinnikovs | Exploring the rules for classical complement pathway activation by antibody pairs with co-dependent oligomerization |
| 158 | P-095 | Complement therapeutics | A. Inkeri Lokki | Eculizumab in severe HELLP syndrome – a case report |
| 12 | P-096 | Complement therapeutics | Sora Suzuki | Tumor-derived Factor B Drives Tumor Growth and anti-PD-1 resistance in STK11-mutant Lung Adenocarcinoma |
| 3 | P-098 | Complement-related diseases | Jillian Hall | Renal Pathology as a Predictor of Complement Dysregulation in C3 Glomerulopathy |
| 24 | P-100 | Complement-related diseases | Angela Nelson | Age-Dependent Plasma Factor D Levels and Their Clinical Implications in Complement-Mediated Kidney Diseases |
| 27 | P-102 | Complement-related diseases | Stefan Sonderegger | The Complement C3a Receptor Regulates the Tumour Microenvironment |
| 44 | P-104 | Complement-related diseases | Zoltán Prohászka | Different patterns of complement activation markers are present in acute and chronic adult primary ITP patients |
| 46 | P-105 | Complement-related diseases | Mari Humalajoki | Characterization of inherited C3 deficiency – a patient case |
| 48 | P-106 | Complement-related diseases | Christopher Culek | Antibodies in the Healthy Population Influence Convertase Formation |
| 64 | P-108 | Complement-related diseases | Adrian Iliescu | The role of C3 in steatotic liver disease |
| 73 | P-110 | Complement-related diseases | Veronique Fremeaux-Bacchi | A new screening approach to identify autoantibodies dysregulating the C3bBb convertase in C3 glomerulopathy and immunoglobulin-mediated membranoproliferative glomerulonephritis |
| 77 | P-112 | Complement-related diseases | Sang Won Cheung | Doxycycline inhibits MMP-9 and inactivates microglia to reduce PNN breakdown and preserve motor neurons in SOD1(G93A) mice. |
| 78 | P-113 | Complement-related diseases | TAKASHI ODA | Analysis of circulating immune complexes in serum of patients with ANCA-associated glomerulonephritis |
| 87 | P-114 | Complement-related diseases | EMMA DILETTA STEA | Beyond Systemic Complement Dysregulation: The Active Contribution of Renal Cells to Complement Dysregulation in C3 Glomerulopathy |
| 89 | P-115 | Complement-related diseases | Kok Yung Lee | Complement is dysregulated in Huntington’s disease in mouse and man. |
| 107 | P-117 | Complement-related diseases | Sai Yarlagadda | Modulation of Complement-Mediated Inflammation in the mdx Mouse Model of Duchenne Muscular Dystrophy by PK007 |
| 115 | P-119 | Complement-related diseases | Cecelia Fierce | Assessing C3 Nephritic Factor Function Using Luminex-Based Formation and Stabilization Assays |
| 116 | P-120 | Complement-related diseases | Carla M Nester | VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN |
| 124 | P-122 | Complement-related diseases | Linnea Lindelöf | Distinct associations of the lectin pathway proteins MASP-2, MASP-3, and MAP-1 with clinical and serological profiles in Systemic Lupus Erythematosus |
| 137 | P-124 | Complement-related diseases | Stephanie Cook | Features of Circulating Factor H Immune Complexes in Complement-Mediated Diseases |
| 138 | P-125 | Complement-related diseases | Sydney S Jellison | Detecting FH–Anti-FH Immune Complexes in MGRS-C3G |
| 144 | P-127 | Complement-related diseases | Sümeyye Erdemci-Evin | Senescent erythrocytes as a trigger of complement activation and implications for breakthrough haemolysis in Paroxysmal Nocturnal Haemoglobinuria patients |
| 145 | P-128 | Complement-related diseases | Kathryn Hok | Single-cell Transcriptomic Changes in Mouse Hearts during Collagen-Induced Arthritic Inflammation |
| 153 | P-131 | Complement-related diseases | Meng Tan | The evaluation of clinical scoring system in complement mediated-TMA patients |
| 159 | P-132 | Complement-related diseases | A. Inkeri Lokki | Genetic C4 deficiency in lower extremity peripheral arterial disease |
| 32 | P-135 | Non-canonical functions of complement | Sandra Parker | Complement C5aR1 Modulates Excitatory Synaptic Transmission in Cortical Pyramidal Neurons via a Calcium-Independent Mechanism |
| 45 | P-137 | Non-canonical functions of complement | Katja Kähler | Pregnancy complications in C5aR2-deficient mice are caused by an altered uterine immune cell network |
| 68 | P-138 | Non-canonical functions of complement | Natalia Kunz | A ‘sweet spot’ for complement receptor CD46 activity: CYT-1 regulates glycolytic and moonlighting functions of glycolytic enzymes during human CD4+ T cell activation |
| 82 | P-142 | Non-canonical functions of complement | Stine Kristensen | Exploring the role of intracellular C3 in activation of the NLRP3 inflammasome in human macrophages |
| 83 | P-143 | Non-canonical functions of complement | Dennis Niese | Neutrophil Plasticity in Epidermolysis Bullosa Acquisita: Bridging Innate and Adaptive Immunity via C5aR2 Signaling |
| 101 | P-145 | Non-canonical functions of complement | Titaya Lerskiatiphanich | Investigating complement receptor C3aR1 signalling in metabolic dysfunction in the R6/1 mouse model of Huntington’s Disease |
| 104 | P-146 | Non-canonical functions of complement | Nicolas Merle | Peptide-mediated modulation of T cell-expressed complement-like CD109boosts T cell anti-tumor responses |
| 132 | P-150 | Non-canonical functions of complement | Véronique Rossi | HMGB1 cleavage by C1s modulates the pro-inflammatory signal induced by TLR2 |
| 160 | P-151 | Non-canonical functions of complement | Tilo Freiwald | Inflammatory cytokines drive local C3 transcription to regulate metabolic reprogramming in kidney epithelial cells and subsequent fibrosis |
| 15 | P-155 | Preclinical models to study complement | Jannes Felsch | A Versatile Screening Platform to Guide Applications for the FH-Recruiting Peptide 5C6 on Non-Self Surfaces |
| 95 | P-160 | Preclinical models to study complement | Grace Risby-Jones | Investigating the Role of Neuronally-expressed C5aR1 in Motor Neuron Disease |
| 96 | P-161 | Preclinical models to study complement | Jianina Marallag | A detrimental role for complement C5aR1 activation in Huntington’s disease |
| 97 | P-162 | Preclinical models to study complement | Alana R. Julianisya | Complement C3a receptor signalling mitigates motor neuron degeneration by modulating neurotoxic astrocytes |
| 98 | P-163 | Preclinical models to study complement | Melina Haritopoulou-Sinanidou | CD93: A New Complement-Linked Target for Immunomodulation and wound healing in SCI |
| 164 | P-165 | Preclinical models to study complement | Haydn E. Rich | Effects of Cannabinoid receptor-1 Antagonist MRI-1867 on C5ar1 Signaling in Attenuating Lung Remodeling in Mice Induced with Experimental Arthritis |
| 165 | P-166 | Preclinical models to study complement | David Eikrem | TiO2 nanoparticles act as an Alternative Pathway-specific C3 inhibitor |
| 166 | P-167 | Diagnostics and monitoring | Sadam Yaseen | CIMED: A High-Serum Concentration Diagnostic Platform for Complement Pathway Activity and Drug Response Monitoring in Patients |
| 167 | P-168 | Diagnostics and monitoring | Tam Cung | Point-of-Care Assessment of sC5b-9: A Reliable Quantitative Tool for Rapid Detection of Complement Activation |
| 168 | P-169 | Evolution and function | Miki Nakao | Evolutionary Insights into the Complement System: Functional Diversification and Ancestral Mechanisms in Bony Fish |
| 169 | P-170 | Complement-related diseases | Laura Lucientes Continente | Classical and Lectin Pathway Activation in ANCA-Associated Vasculitis with Kidney Involvement: Prognostic Value and Comparison with Alternative Pathway Components |
| 170 | P-171 | Complement-related diseases | Hormaz Dastoor | Rescue Therapy with Pegcetacoplan in a Patient with C3 Glomerulopathy: A Case Report |